GameStop Corp. vs Nuvalent Inc — how do they compare? GameStop Corp. trades at $22.38 (market cap $9.99B), while Nuvalent Inc trades at $123.96 (market cap $9.81B). The key difference: GameStop Corp. and Nuvalent Inc are close in size by market cap, and Nuvalent Inc is trading nearer its 52-week high, GameStop Corp. nearer its low. Which is the better fit depends on your goals.
| GME | NUVL | |
|---|---|---|
Market Cap | $9.99B | $9.81B |
Sector | Consumer Cyclical | Technology |
52-Week High | $27.69 | $123.96 |
52-Week Low | $19.94 | $72.16 |
Enterprise Value | $5.96B | $8.52B |
Signals from Pluang's Aura AI — not financial advice
GME trades at $22.43, up 1.82% today, with a bullish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.30 exceeding the $0.16 estimate. Revenue for 2025 was $3.82 billion, with net income of $131.3 million, marking a significant turnaround from prior losses. Recent news highlights a partnership with Uber Eats and a proposed eBay acquisition as strategic growth catalysts.
The outlook is mixed; fundamentals show improving profitability and a robust balance sheet with $4.77 billion cash, but revenue declines and competitive pressures from digital game distribution pose risks. Analyst sentiment is cautious with only 16.7% buy ratings. Key opportunities include EBITDA guidance exceeding $600 million for 2026, while execution risks around the eBay bid and industry shifts remain headwinds.
Nuvalent (NUVL) trades at $123.96, unchanged on the day, amid a pending $124 per share acquisition by GSK. The stock shows a bullish technical signal with moving averages supporting upside, though RSI levels suggest overbought conditions. Fundamentally, the company remains unprofitable with negative ROE and ROA, while cash flow is sustained by financing activities. Recent news is dominated by merger investigations and strategic rationale for the GSK deal.
The investment outlook hinges on the acquisition closing at $124, offering limited upside from current levels. Risks include shareholder litigation and regulatory scrutiny, but the deal provides a clear exit amid ongoing losses. Analyst sentiment is mixed with a slight hold bias, reflecting uncertainty around deal completion and fairness.
Trailing returns across standard periods
Latest headlines on both assets
Global Market Group Ltd. operates an Internet website that connects Chinese manufacturers with international buyers. The Company's customers can post company profiles and product information in standardized formats; post product listings; and trade leads.
Read more on GME →Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →